Accuracy of non-ECG-gated computed tomography angiography of the chest in assessment of left-sided cardiac chamber enlargement.

PURPOSE: To determine whether measurement of left ventricular (LV) and left atrial (LA) diameters on nongated computed tomography angiography (CTA) can detect left atrial and left ventricular enlargement (LAE and LVE) with high specificity. MATERIALS AND METHODS: Ninety-nine patients who had undergone both nongated CTA of the chest and echocardiography within 1 week constituted the pilot group. On CTA, LA and LV diameters were measured in the axial plane and on a 3-chamber-view multiplanar reconstruction. These measurements were compared with echocardiography results. Receiver operating characteristic (ROC) curves were then generated to determine optimal cutoff values for diagnosis of LAE and LVE. These thresholds were applied to a validation group (n = 203), and sensitivities and specificities for cutoff values were determined. Simple κ-coefficients were calculated for interobserver agreement. RESULTS: In the pilot group, axial measurements of the LA and LV diameters were superior to multiplanar reconstruction measurements based on areas under the ROC (LV: 0.82 vs. 0.76, LA: 0.87 vs. 0.82). Using the ROC results, cutoff values of 5.5 and 4.5 cm were chosen for LVE and LAE, respectively. These thresholds were applied to the validation group, achieving an average sensitivity and specificity for LAE of 53% [confidence interval (CI): 37%-71% and 94% (89%-97%)], respectively. Average sensitivity and specificity for LVE were 41% (CI: 23%-59%) and 99% (CI: 96%-100%), respectively. Kappa coefficients for diagnosis of LAE and LVE were 0.70 and 0.81, respectively. CONCLUSION: Thresholds for LA and LV diameter on nongated CTA can be chosen to provide specific, but not sensitive, detection of LAE and LVE.

Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data.

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Recent studies have indicated that inflammation might play a significant role in the initiation, maintenance, and perpetuation of AF. Inflammatory markers such as interleukin-6 and C-reactive protein are elevated in AF and correlate to longer duration of AF, success of cardioversion, and thrombogenesis. Furthermore, the inflammatory process might be modulated by the use of statins, angiotensin-converting enzyme inhibitors, or glucocorticoids. The purpose of this study is to analyze the current published reports on the relationship between inflammation and AF and the potential therapeutic options available to modulate the inflammatory milieu in AF.

Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials.

BACKGROUND: Observational studies routinely describe a significant gap between rates of blood pressure control in routine diabetes care compared with those achieved in randomized controlled trials (RCTs). METHODS: We performed a systematic review of the literature to identify co-maneuvers used in RCTs, defined as ancillary activities or agents administered before, during, or immediately after the main agent under investigation (ie, principal maneuver), but not effectively translated to routine diabetes care. We searched multiple databases for RCTs evaluating the efficacy of treatments for hypertension control in adults with type 2 diabetes mellitus. We considered only phase III human studies of interventions that achieved blood pressure control and scrutinized all elements related to the implementation of the principal maneuver in each candidate study. These elements were then sorted into a taxonomy of co-maneuvers. RESULTS: Nearly all eligible RCTs used highly consistent groups of co-maneuvers. These typically began with (1) the use of consensual and clearly stated blood pressure goals; (2) frequent visits in which blood pressure levels were measured and compared with predefined goals; and, if the goal was not attained, (3) modifications to the treatment based on a detailed action plan that included communication of adverse events. Patient education, feedback to clinicians, and interventions for medication adherence were not commonly used among eligible trials. CONCLUSIONS: Clinicians should translate key behavioral co-maneuvers along with clinically proven treatments for hypertension control in diabetes. These co-maneuvers are conceptually similar to collaborative goal setting and action planning interventions used in innovative chronic care programs.